Variability in the Management of Line-related Upper Extremity Deep Vein Thrombosis

Overview

Journal Phlebology

Specialty Cardiology & Vascular Diseases

Date 2019 Feb 2

PMID 30704347

Citations 1

Authors

Rafael Cires-Drouet

Jashank Sharma

Tara McDonald

John D Sorkin

Brajesh K Lal

Affiliations

Soon will be listed here.

Citing Articles

Prevalence and clinical outcomes of hospitalized patients with upper extremity deep vein thrombosis.

Cires-Drouet R, Durham F, Sharma J, Cheeka P, Strumpf Z, Cranston E J Vasc Surg Venous Lymphat Disord. 2021; 10(1):102-110.

PMID: 34089941 PMC: 9000923. DOI: 10.1016/j.jvsv.2021.05.007.

References

Schulman S, Kearon C, Kakkar A, Mismetti P, Schellong S, Eriksson H . Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24):2342-52. DOI: 10.1056/NEJMoa0906598. View

Joffe H, Kucher N, Tapson V, Goldhaber S . Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation. 2004; 110(12):1605-11. DOI: 10.1161/01.CIR.0000142289.94369.D7. View

Kreuziger L, Onwuemene O, Kolesar E, Crowther M, Lim W . Systematic review of anticoagulant treatment of catheter-related thrombosis. Thromb Res. 2015; 136(6):1103-9. DOI: 10.1016/j.thromres.2015.08.020. View

Agnelli G, Buller H, Cohen A, Curto M, Gallus A, Johnson M . Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369(9):799-808. DOI: 10.1056/NEJMoa1302507. View

Kovacs M, Kahn S, Rodger M, Anderson D, Andreou R, Mangel J . A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost. 2007; 5(8):1650-3. DOI: 10.1111/j.1538-7836.2007.02613.x. View

Levy M, Albuquerque F, Pfeifer J . Low incidence of pulmonary embolism associated with upper-extremity deep venous thrombosis. Ann Vasc Surg. 2012; 26(7):964-72. DOI: 10.1016/j.avsg.2011.12.016. View

Malinoski D, Ewing T, Patel M, Nguyen D, Le T, Cui E . The natural history of upper extremity deep venous thromboses in critically ill surgical and trauma patients: what is the role of anticoagulation?. J Trauma. 2011; 71(2):316-21. DOI: 10.1097/TA.0b013e318222f3f4. View

Artino Jr A, Durning S, Sklar D . Guidelines for Reporting Survey-Based Research Submitted to Academic Medicine. Acad Med. 2018; 93(3):337-340. DOI: 10.1097/ACM.0000000000002094. View

Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H . Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2):315-352. DOI: 10.1016/j.chest.2015.11.026. View

10.

Bauersachs R, Berkowitz S, Brenner B, Buller H, Decousus H, Gallus A . Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26):2499-510. DOI: 10.1056/NEJMoa1007903. View

11.

Saber W, Moua T, Williams E, Verso M, Agnelli G, Couban S . Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost. 2010; 9(2):312-9. PMC: 4282796. DOI: 10.1111/j.1538-7836.2010.04126.x. View

12.

Agnelli G, Buller H, Cohen A, Curto M, Gallus A, Johnson M . Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2012; 368(8):699-708. DOI: 10.1056/NEJMoa1207541. View

13.

Kucher N . Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med. 2011; 364(9):861-9. DOI: 10.1056/NEJMcp1008740. View

14.

Lavau-Denes S, Lacroix P, Maubon A, Preux P, Genet D, Venat-Bouvet L . Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study. Cancer Chemother Pharmacol. 2013; 72(1):65-73. DOI: 10.1007/s00280-013-2169-y. View

15.

Davies G, Lazo-Langner A, Gandara E, Rodger M, Tagalakis V, Louzada M . A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2). Thromb Res. 2017; 162:88-92. DOI: 10.1016/j.thromres.2017.04.003. View

16.

Lamontagne F, McIntyre L, Dodek P, Heels-Ansdell D, Meade M, Pemberton J . Nonleg venous thrombosis in critically ill adults: a nested prospective cohort study. JAMA Intern Med. 2014; 174(5):689-96. DOI: 10.1001/jamainternmed.2014.169. View

17.

Kearon C, Akl E, Comerota A, Prandoni P, Bounameaux H, Goldhaber S . Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e419S-e496S. PMC: 3278049. DOI: 10.1378/chest.11-2301. View

18.

Prandoni P, Noventa F, Lensing A, Prins M, Villalta S . Post-thrombotic syndrome and the risk of subsequent recurrent thromboembolism. Thromb Res. 2016; 141:91-2. DOI: 10.1016/j.thromres.2016.03.010. View

19.

OGrady N, Alexander M, Burns L, Dellinger E, Garland J, Heard S . Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 2011; 52(9):e162-93. PMC: 3106269. DOI: 10.1093/cid/cir257. View

20.

Young A, Billingham L, Begum G, Kerr D, Hughes A, Rea D . Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet. 2009; 373(9663):567-74. DOI: 10.1016/S0140-6736(09)60205-1. View